Phase II study of Temozolomide monotheraphy in patients with first line treatment-refractory neuroendocrine carcinoma

Phase II study of Temozolomide monotheraphy in patients with first line treatment-refractory neuroendocrine carcinoma - Second line treatment of Temozolomide in neuroendocrine carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010549

Enrollment

Registered

2013-04-20

Start date

2013-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroendocrine carcinoma (Grade3)

Interventions

Patients were treated temozolomide (150mg/m2) orally on day1 to 5 of 28-day cycle.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: pathological diagnosed neuroendocrine carcinoma Grade3 Any primary sites are included The cases of refractory first-line treatment ECOG PS 0-1 granulocyte count > 1500 platelet count > 10000

Exclusion criteria

Exclusion criteria: cerebral vascular disease untreatment bone fracture uncontrolable ulcer tendency of bleeding another major carcinoma cerebral vascular disease active infection HBV hepatitis or carrier uncontrolable hypertension intestinal pneumonia past history of intake aboutimmunosuppressive agents tubeluclosis cardiac disease pregnancy

Design outcomes

Primary

Measure	Time frame
overall response rate	—

Secondary

Measure	Time frame
overall survival	—

Countries

Japan

Contacts

Public ContactKobayashi Noritoshi

Yokohama City University Hospital Clinical Oncology

norikoba@yokohama-cu.ac.jp045-787-2623

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026